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Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide; hence novel treatments
for this malignancy are eagerly needed. Since natural-based compounds represent a rich source
of novel chemical entities in drug discovery, we have focused our attention on tambjamines,
natural compounds isolated from marine invertebrates that have shown diverse pharmacological
activities. Based on these structures, we have recently identified the novel indole-based tambjamine
analog 21 (T21) as a promising antitumor agent, which modulates the expression of apoptotic
proteins such as survivin. This antiapoptotic protein plays an important role in carcinogenesis
and chemoresistance. In this work, we have elucidated the molecular mechanism by which the
anticancer compound T21 exerts survivin inhibition and have validated this protein as a therapeutic
target in different lung cancer models. T21 was able to reduce survivin protein levels in vitro by
repressing its gene expression through the blockade of Janus kinase/Signal Transducer and Activator
of Transcription-3 (JAK/STAT3)/survivin signaling pathway. Interestingly, this occurred even when
the pathway was overstimulated with its ligand interleukin 6 (IL-6), which is frequently overexpressed
in lung cancer patients who show poor clinical outcomes. Altogether, these results show T21 as a
potent anticancer compound that effectively decreases survivin levels through STAT3 inhibition in
lung cancer, appearing as a promising therapeutic drug for cancer treatment.
Keywords: natural-based compound; anticancer therapy; lung cancer; survivin; apoptosis; STAT3
1. Introduction
Lung cancer is the leading cause of cancer-related deaths in both men and women worldwide,
accounting for more than 2.1 million new cases and more than 1.8 million deaths estimated in
2018 [1]. This malignancy is broadly categorized into small cell lung cancer (SCLC) and non-small
cell lung cancer (NSCLC), which represents the 85% of all lung cancers diagnosed. NSCLC is further
divided in three major subtypes based on their histology: adenocarcinoma, squamous cell lung
carcinoma (SQCLC) and large cell carcinoma, corresponding to 45–50%, 25–30% and 5–10% of all
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diagnosed NSCLC, respectively [2]. The current standard of care for lung cancer differs according
to the tumor histological type, the stage of cancer, possible side effects, and overall patient health.
Considering this, surgical resection, radiotherapy, conventional platinum-based doublet chemotherapy
(cisplatin generally in combination with pemetrexed/Alimpta® or gemcitabine), immunotherapy (anti
PD-1, mostly nivolumab/Opdivo®)), and targeted therapy are the main options to treat lung cancer [3].
Nevertheless, despite all the available therapeutic options, the five-year survival rate of lung cancer is
low, 18.6%, according to the National Cancer Institute (NCI). Therefore, novel therapeutic strategies
should be developed to increase the therapeutic options available for the treatment of this malignancy.
Natural-based compounds constitute an important research area for cancer drug discovery,
with numerous compounds showing therapeutic potential in most cancer types. Interestingly,
over 70% of anticancer compounds in clinical use derive from natural products, such as the marine
organism-derived compounds cytarabine (Cytosar), travectedin (Yondelis), eribulin mesylate (Halaven)
and the conjugated antibody brentuximab vedotin (Acentris) [4]. In particular, marine organisms are
gaining interest for providing a huge array of biologically active metabolites for the development
of new anticancer agents. The natural alkaloids tambjamines, originally isolated from marine
invertebrates, have shown a wide spectrum of pharmacological properties [5]. In this regard, we have
demonstrated that the indole-based tambjamine analog 21 (T21) exerts a potent anticancer effect
in vitro and a significant therapeutic effect, with a favorable safety profile, in vivo in lung cancer
mice models [6]. Moreover, T21 was able to modulate apoptotic protein levels, including survivin.
As a member of the inhibitor of apoptosis (IAP) family, survivin plays an important role in
tumorigenesis, metastasis and therapy resistance by promoting cell division and inhibiting apoptosis [7].
Furthermore, survivin is overexpressed in cancer cells, while in most normal finally differentiated
tissues is almost undetectable [8]. Altogether, these features advocate survivin as an ideal therapeutic
target to treat cancer and hence, T21 may be a promising future chemotherapeutic agent. In fact,
several molecular approaches that block survivin expression and/or function are emerging as promising
therapeutic strategies in cancer by sensitizing tumor cells to apoptosis, minimally affecting non-tumor
cells [9].
Therefore, in this work we have deeply analyzed, for the first time, the molecular mechanism
of action by which a recently described natural-derived compound called T21 inhibits survivin,
inducing its anticancer effects in vitro as well as in in vivo mice models, validating survivin as a
promising therapeutic target for lung cancer treatment.
2. Materials and Methods
2.1. Human Samples
Fresh squamous cell lung carcinoma tissue and adjacent non-tumor lung tissue samples were
obtained from patients during resection surgery at Bellvitge University Hospital in Barcelona, Spain.
The study was conducted in accordance with the Declaration of Helsinki ethical guidelines and
informed consent was obtained from all patients included in the study. All study protocols were
approved by the Clinical Research Ethics Board of Bellvitge University Hospital and by the local Ethics
Committee (PR003/13). The histological typing was confirmed by the Pathology Department at the
aforementioned Hospital. All the human tissue samples were preserved in RNAlater™ (Cat#76104,
Qiagen) and stored at liquid nitrogen before being processed.
2.2. Reagents
Tambjamine-21 analogue (T21) was synthesized as previously reported [6], dissolved at
10 mmol/L in dimethyl sulfoxide (DMSO) and stored at −20 ◦C. Cycloheximide (CHX; Cat#C7698-IG)
from Sigma-Aldrich was dissolved in ethanol at a stock solution of 100 mg/mL and stored at
−20 ◦C. Interleukin 6 (IL-6; Cat#IL006) was purchased from EMD Millipore and dissolved in 1×
phosphate-buffered saline (PBS; Cat#02-020, Biological Industries, Beit Haemek, Israel) with calcium
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and magnesium supplemented with 0.1% bovine serum albumin (BSA; Cat#A7906, Sigma-Aldrich,
St Louis MO, USA) at a stock solution of 100 µg/mL and stored at −80 ◦C. Hoechst 33,342 (Cat# B2261)
was purchased from Sigma-Aldrich.
2.3. Antibodies
The antibodies used in this study were obtained from the following sources: anti-survivin (71G4B7,
Cat#2808), anti-XIAP (3B6, Cat#2045), anti-phospho-JAK1 (Y1034/1035; Cat#3331), anti-phospho-STAT3
(Y705; D3A7, Cat#9145), anti-cleaved PARP (Cat#5625T), anti-cleaved caspase 3 (Cat#9664) and
anti-phospho-JAK2 (Y1007/1008; Cat#3771) from Cell Signaling Technology Inc. (Beverly, MA,
USA); anti-actin (I-19, Cat#sc-1616), anti-GAPDH (0411, Cat#sc-47724), anti-JAK1 (B-3, Cat#376996),
anti-phospho-STAT3 (Y705; B-7, Cat#sc-8059), anti-STAT3 (F-2, Cat#sc-8019), from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA); anti-vinculin (Cat#V-4505) from Sigma-Aldrich.
Antibody binding was detected with donkey anti-mouse IgG-HRP (Cat#A16017), donkey anti-rabbit
IgG-HRP (Cat#A16029) and donkey anti-goat IgG-HRP (Cat#A15999) from Thermo Fisher Scientific
Inc. (Waltham, MA, USA); Alexa Fluor™ 488-conjugated donkey anti-mouse (Cat#A31572, Molecular
Probes, Eugene, OR, USA) was used for antibody binding detection in immunofluorescence assays.
2.4. Cell Lines and Culture Conditions
Human cell lines SW900 and H520 (squamous lung carcinoma), A549 (lung adenocarcinoma),
DMS53 (small cell lung carcinoma) and HFL-1 (lung fibroblasts), were obtained from the American
Type Culture Collection (ATCC). SQCLC, adenocarcinoma and lung fibroblasts cells were cultured
(passage number 10–25) in Roswell Park Memorial Institute medium (RPMI, Cat# 01-104), Dulbecco’s
modified Eagle’s medium (DMEM, Cat#01-055) and Ham’s F-12 (Cat#01-095) (Biological Industries),
respectively. All of them were supplemented with 10% heat-inactivated fetal bovine serum (FBS Gibco™;
Cat#10270106, Life Technologies), 100 units/mL penicillin, 100 µg/mL streptomycin, and 2 mM
L-glutamine (all from Biological Industries). Non-essential amino acids (NEAA; Cat#X0557, Biowest;
1:100) were also used for HFL-1 culture (Biological Industries). 15 mM of HEPES buffer solution
(Cat#03-025, Biological Industries) was also used for H520 culture. Cells were grown at 37 ◦C in
a humidified incubator (Thermo Fisher Scientific Inc.) with 5% CO2 atmosphere. The cells were
mycoplasma tested using a standard PCR technique after thawing.
2.5. Gene Expression Analysis
Gene expression levels of BIRC5 were evaluated by Reverse Transcription quantitative-PCR
(RT-qPCR) analysis. Total RNA was isolated and purified from 30 mg of frozen tissue samples
using the column-based RNeasy Mini Kit (Qiagen) and following the manufacturer’s standard
protocol. Total RNA concentration and purity were checked in a nano spectrophotometer
(Implen GmbH, Munchen, Germany) and integrity was analyzed using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). Samples with higher RNA integrity number (RIN)
were selected (7 lung cancer samples and their paired normal tissue samples from the same
patient). RNA amounts from selected tissue samples were equally pooled to create a sample
(Σnon-tumoral and Σtumoral) and their concentration, purity and integrity were re-checked. For
the reverse transcription, 1 µg of total RNA was used for cDNA synthesis using a mixture of
random hexamers and oligo-dT primers and following the RT2 First Strand Kit protocol (Qiagen).
Then, reverse transcription was confirmed through actin beta (ACTB) gene amplification by standard
PCR procedure (BIOTAQ DNA Polymerase; BIOLINE). For survivin expression analysis in A549
and SW900 cells, 1.25 × 105 cells/mL were seeded and after 24 h they were treated in absence
or presence of T21 for 6 or 16 h (IC50 concentrations). RNA was purified and cDNA obtained
as described above. Specific oligonucleotide primers and probes for BIRC5 (Hs00153353_m1),
and ACTB (Hs99999903_m1), were purchased as Assay-on-Demand Gene Expression Products
(Applied Biosystems). TaqMan PCR reactions were performed on cDNA samples using TaqMan
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Universal PCR Master Mix (Applied Biosystems, Fosters city, CA, USA) and ABI PRISM 7900 HT Fast
Real-Time PCR system (Applied Biosystems). Gene expression levels were quantified and normalized
using ACTB as a house keeping gene and relative mRNA expression was calculated in relation to the
healthy samples. Ct values were determined using ExpressionSuite software (version 1.0.3, Applied
Biosystems) and are presented as mean ± SD of three independent experiments.
2.6. Cell Viability Assays
Cell viability was evaluated using the methylthiazoletetrazolium (MTT, Sigma-Aldrich,
Merck KGaA) colorimetric assay. Cells were harvested (105 cells/mL) in 96-well plates and allowed to
grow overnight. At the following day, T21 was added to the cells at different ranging concentrations
(0.8–100 µmol/L) or vehicle solution (DMSO, Sigma-Aldrich, Merck KGaA) to control cells. Cells were
incubated for 24 h and after the treatment period, 10 µL of MTT (5 mg/mL) were added and the
plates were incubated for 2 h at 37 ◦C. Crystals were dissolved in 100 mL of DMSO and reading was
done in a spectrophotometer at 570 nm using a multiwell plate reader (Multiskan FC, Thermo Fisher
Scientific Inc.). Cell viability and inhibitory concentration (IC) values were obtained using GraphPad
Prism V5.0 for Windows (GraphPad Software). All data are shown as the mean value ± SD of three
independent experiments.
2.7. Clonogenic Assay
A549 cells at 105 cells/mL were seeded (1 mL) in 24-well plate and incubated overnight to allow
attachment. Cells were treated for 24 h with T21 at 2.5–10 µM and the same percentage of DMSO was
added to the control cells. Then, cells were counted and 200 viable cells were seeded in a final volume
of 3 mL in a 6-well plate and allowed to growth for 1 week. Medium was removed and cell colonies
were fixed coloured with a mixture of glutaraldehyde (6% v/v) and crystal violet (0.5% w/v) for 20 min
at room temperature and were counted.
2.8. Western Blot Analysis
For the evaluation of the molecular effects after 48 h of survivin silencing, A549 and H520 cells
were seeded in 6-wells plates at a density of 1.25 × 105 cells/mL in a volume of 2 mL of medium without
antibiotics. The day after, cells at 70–90% of confluence were transfected with 250 pmol of small
interfering RNA (siRNA) against survivin (Cat#4390824; Thermo Fisher Scientific Inc.) or scrambled
siRNA (Cat#4390843; Thermo Fisher Scientific Inc.) using Lipofectamine® 2000 reagent (Thermo Fisher
Scientific Inc.) and following manufacturer’s standard protocol.
For the study of T21 cellular effects, A549, SW900, H520 and DMS53 were seeded in 100-mm cell
culture plates (1.25 × 105 cells/mL) and allowed to grow for 24 h. Then they were treated with different
inhibitory concentrations (IC) of T21 compound (IC25, IC50 and IC75 values in µM) for 24 h or the IC50
value during different time periods (4, 8, 16, 24 h).
For protein synthesis inhibition, A549 and SW900 were seeded in a 6-well plate (1.25 × 105
cells/mL) and allowed to grow for 24 h. Then they were treated with CHX at 100 µg/mL for 30 min
followed by T21 treatment at IC50 during 24 h.
For the stimulation of STAT3 pathway with IL-6, A549 cells were seeded in 60-mm culture plates
(1.25 × 105 cells/mL) for 24 h, and then were starved in serum-free medium for at least another 12 h.
Next, cells were stimulated with IL-6 at different concentrations (1, 5 and 10 ng/mL) for 30 min.
Similarly, after starvation, A549 cells were pretreated with IC50 T21 for 4 h followed by 5 ng/mL of IL-6
stimulation for 30 min.
In all experiments, whole cell lysates, from the selected tissue samples or from cultured cells,
were prepared with ice cold lysis buffer containing 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate,
50 mmol/L sodium fluoride, 40 mmol/L β-glycerophosphate, 200 µmol/L sodium orthovanadate,
1 mmol/L phenylmethylsulfonyl fluoride (all from Sigma-Aldrich), and protease inhibitor cocktail
(Cat#11836170001, Roche Diagnostics) in 1× PBS followed by its homogenization, using a tissue
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grinder (Cat#431-0100, VWR International) in case of the tissue samples. Protein concentration was
determined by BCA protein assay (Cat#23225, Pierce™, Thermo Fisher Scientific Inc.) using BSA
protein (Sigma-Aldrich) as a standard. For western blot analysis, 40–50 µg of protein extract were
first separated by SDS-PAGE and transferred to Immobilon-P polyvinylidene difluoride (PVDF)
membranes (EMD Millipore, Merck KGaG). Membranes were blocked in either 5% non-fat dry milk
or BSA, both diluted in Tris-buffered saline (TBS)-Tween (50 mmol/L Tris-HCl pH 7.5, 150 mmol/L
NaCl, 0.1% Tween-20) for 1 h and then incubated overnight with primary antibodies, according to the
manufacturer’s instructions. Actin, vinculin or GAPDH (Glyceraldehyde 3-phosphate dehydrogenase)
were used as gel loading controls. The results shown are representative of Western blot data
analysis obtained from at least three independent experiments. Images were captured on an Image
Quant LAS 500 (GE Healthcare) using ECL™ Western blotting detection reagent (Cat#RPN2106,
Amersham, GE Healthcare) and band densitometries were retrieved using the Image Studio Lite
software (v5.2, LI-COR Biosciences).
2.9. Immunofluorescence Staining
HFL-1, A549 and SW900 cells (1.25 × 105 cells/mL) were seeded in a 12-well plate containing
FBS-coated glass coverslips for 24 h. For the IL-6 experiment, A549 cells (1.25 × 105 cells/mL) were
seeded in a 12-well plate containing FBS-coated glass coverslips for 24 h and then were starved in
serum-free medium for at least another 12 h. Then, cells were pretreated with IC50 T21 for 4 h followed
by 5 ng/mL of IL-6 stimulation for 30 min. Next, all cells were washed twice with 1× PBS and fixed
with 4% paraformaldehyde for 20 min. Fixed cells were permeabilized by 0.2% Triton X-100 and then
blocked with 1% BSA in 1× PBS for 1 h. Cells were incubated overnight at 4 ◦C with anti-survivin
antibody at a dilution of 1:500 or anti-phospho-STAT3 (Cell Signaling) at a dilution of 1:100. Cells were
then washed with 1× PBS and incubated with Alexa Fluor™ 488-conjugated goat anti-rabbit (Molecular
Probes) at 1:400 dilution for 1 h at room temperature. At the same time, the cell nuclei were stained with
2 µg/mL hoechst 33,342 (Cat# B2261, Sigma-Aldrich). Afterwards, coverslips were washed with 1× PBS
and were placed on the slides using Mowiol™ (Sigma-Aldrich). The immunofluorescence images
were acquired using a Carl Zeiss LSM 880 spectral confocal laser scanning microscope (Carl Zeiss
Microscopy GmbH, Jena, Germany) equipped with a multiline argon laser (458 nm, 488 nm and
514 nm), 405nm and 561nm diode lasers and 633 nm He/Ne laser (Centres Científics i Tecnològics,
Universitat de Barcelona, Bellvitge Campus, Barcelona, Spain) using a 63× oil immersion objective
(1.4 numerical aperture) an image resolution of 1024 × 1024 pixels. Representative images from three
independent experiments are shown.
2.10. Immunohistochemistry Analysis
For in vivo studies, five-week-old female Crl:NU-Foxn1nu mice strain (Envigo) were used to
generate a subcutaneous xenograft model. All animal studies were approved by the Autonomic Ethic
Committee (Generalitat de Catalunya) under the protocol 9111. DMS53 cells (4.5 × 106 cells) suspended
in a 1:1 solution of RPMI1460:Matrigel (BD Bioscience) were implanted subcutaneously in the flank of
mice. Mice bearing homogenous subcutaneous tumors (approximately 150–200 mm3) were randomly
allocated to two treatment groups (n = 7/treatment) and intraperitoneally administrated with T21
(diluted in 7.5% DMSO/0.8% Tween-80) at a dose of 6 mg/kg in alternated days during 20 days. After the
final dose of the treatment, animals were sacrificed, tumors dissected out and embedded in paraffin for
immunohistochemistry staining as follows: 4 µm sections were cut, deparaffinized and after antigen
retrieval in 10 mmol/L sodium citrate buffer with 0.05% Tween-20 in the microwave at sub-boiling
temperature (95–98 ◦C) for 20 min, slides were washed 2 times with distilled H2O (dH2O) of 5 min
each. Endogen peroxidase was blocked by incubation in 3% H2O2 for 5 min at room temperature
following by washing steps for 5 min twice, with dH2O and PBS. Slides were blocked with normal
goat serum in a 1:30 dilution for 1 h at room temperature and incubated with anti-survivin antibody
diluted 1:400 in PBS overnight at 4 ◦C in a wet chamber. Afterwards, slides were washed 3 times in
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PBS for 5 min each and incubated with secondary antibody coupled with HRP at 1:100 dilution in PBS
for 1 h, at room temperature. Then, slides were washed 3 times with PBS 0.1% Tween-20 for 5 min
each and signal was developed by incubation with DAB (3,3′-diaminobenzidine) (Cat#D8001, Sigma)
for 10 min at room temperature. Finally, slides were washed for 5 min with dH2O, counterstain with
Hematoxylin (Cat#A3865, PanReac AppliChem, Barcelona, Spain), dehydrated, and mounted with
DPX (Cat#100579, Merck, Madrid, Spain). Samples were observed in a Nikon Eclipse E800 microscope
and images were taken with the camera ProgRes CFscan.
2.11. Statistical and Data Mining Analyses
For statistical analysis of single point qPCR results and western blot data, t-Student test and
one-way ANOVA with post hoc Tukey analysis, were carried out using the Statgraphics plus 5.1
statistical Software, respectively. Statistically significant differences, p < 0.05, p < 0.01 and p < 0.001,
are represented by *, ** and ***, respectively.
3. Results
3.1. Survivin Validation as A Promising Therapeutic Target in All Lung Cancer Subtypes
Since the anticancer T21 compound potently decreases the protein levels of the antiapoptotic protein
called survivin, expression levels of this potential therapeutic target were evaluated in tumor samples
from SQCLC patients through both specific qPCR analysis and survivin protein immunodetection
(Figure 1A,B). In accordance with other tumors, BIRC5 was confirmed to be up-regulated more than
19 times in SQCLC samples using qPCR and consequently, survivin expression in tumor samples
was much higher than in non-tumor samples. Furthermore, we wanted to analyze whether this
protein may also be a therapeutic target for all the most prevalent lung cancer histological subtypes.
Hence, we analyzed survivin overexpression in the adenocarcinoma cell line A549, the small cell lung
cancer cell line DMS53 as well as in the SQCLC cell lines, SW900 and H520. All four tumor cell lines
overexpress survivin compared to non-tumor human lung fibroblasts HFL-1 (Figure 1C; Figure S1).
Interestingly, survivin has a dual role in cancer, both promoting cell cycle progression and inhibiting
apoptosis [8]. Therefore, in order to validate survivin as an effective therapeutic target in lung cancer,
we proposed to perform a loss-of-function assay by inhibiting survivin expression. In this context,
A549 and H520 cells were transfected with a siRNA against survivin mRNA or a control siRNA
designed to have no specific target in the cell. After 48 h of transfection, there was no activation of
apoptosis in cells exposed to control siRNA; however, transfection with siRNA against survivin resulted
in a marked activation of caspase 3 in A549 as well as a cleavage of their substrate poly (ADP-ribose)
polymerase (PARP) (Figure 1D). In the case of transfected H520, where the silencing of survivin was
less evident, the increase of the activated form of caspase 3 was more subtle, but also significant
(Figure 1D). Cleaved PARP was also increased in H520 with silenced survivin. Finally, we wanted to
elucidate whether the X-linked inhibitor of apoptosis protein (XIAP), a survivin partner in apoptosis
inhibition, may also be affected after survivin silencing, since its stability against ubiquitin-dependent
degradation is linked to survivin binding [10]. In our cellular models, XIAP also showed a significant
reduction of its protein levels after 48 h of survivin downregulation, although less pronounced than
survivin decrease, both in A549 and H520 cells (Figure 1D,E). Therefore, survivin appears as a potential
therapeutic target in all lung cancer subtypes, suggesting the promising use of compounds targeting
survivin for lung cancer treatment.
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Figure 1. Survivin expression levels in lung cancer tumor samples and survivin functional validation in
cellular models. (A) qPCR validation of BIRC5 expression levels. Fold changes of gene expression were
calculated using β-actin as the housekeeping gene. (B,C), survivin levels were analyzed using whole
cell lysates from patient tissue samples and lung cell lines by Western blot analysis. (D,E), After 48 h of
transfection with siRNA against survivin mRNA, the expression of survivin, XIAP and pro-apoptotic
proteins was analyzed by Western blot analysis in A549 and H520 cell lines. Protein levels were
normalized with their respective loading controls in each blot. Results were obtained from at least
three independent experiments. Bars represent the mean ± SD. Statistically significant results are
indicated as *, p-value < 0.05; **, p-value < 0.01 and ***, p-value < 0.001. C3c, cleaved caspase 3; PARPc,
cleaved PARP.
3.2. Indole-Based Tambjamine Analog 21 (T21) Downregulates Survivin in Lung Cancer In Vitro and In
Vivo Models
To extend the reported cytotoxic properties of T21 (Figure 2A), the effect on cell viability of H520
squamous cell lung cancer cells was also evaluated after treatment with different concentrations of T21
for 24 h, showing similar results than in the other studied cancer cells (Figure 2B). Moreover, the ability
to survive and form colonies after T21 treatment was evaluated in a clonogenic assay in A549 cells
(Figure S2). These cells were treated with T21 during 24 h, counted, and 200 viable cells were seeded in
a new plate with fresh medium for one week. The survival capacity significantly decreased in cells
after T21 treatment, especially in those treated with 10 µM, corroborating the potent cytotoxic effect of
this compound.
In order to characterize in detail the molecular mechanism of action of this anticancer compound,
we analyzed whether T21 was able to inhibit survivin in different lung cancer histological subtypes.
For that purpose, the inhibitory effect of T21 on survivin levels was evaluated in non-small cell lung
cancer SW900, H520 and A549 cells as well as in the small cell lung cancer DMS53 cells. All cells
were treated with T21 at different cell viability inhibitory concentrations for 24 h (IC25, IC50 and IC75
concentrations) (Figure 2B). The results showed a sharp and significant dose-dependent decrease
of survivin in all four cell lines (Figure 2C,D). Furthermore, T21 was also able to decrease, in a
dose-dependent manner, the protein levels of XIAP in A549, H520 and to a lesser extent in SW900 and
DMS53. Hence, these results suggest that the anti-apoptotic proteins survivin and XIAP decrease in a
dose-dependent manner after T21 treatment allowing the induction of apoptosis.
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SW900, H520 and DMS53 cell lines. (E) and (F) A549 and SW900 cells were treated with T21 at IC50 
during different time periods (4, 8, 16, 24 h) followed by survivin and XIAP expression analysis 
through Western blot analysis. Results were obtained from at least three independent experiments. 
Bars represent the mean ± SD. Statistically significant results are indicated as *, p-value < 0.05; **, p-
value < 0.01 and ***, p-value < 0.001. (G) Subcutaneous tumors from implanted DMS53 cells in Crl:NU-
Figure 2. T21 decreases survivin levels in vitro and in vivo. (A) T21 chemical structure.
(B) T21 inhibitory concentration (IC) values calculated in cell viability assays performed in several
lung cancer cell lines. Some IC50 values were previously published in Manuel-Manresa et al. [6].
Values represent mean ± SD in µM. (C,D) After 24 h of treatment with IC25, IC50, IC75 values of T21
(Table S1), the expression of survivin and XIAP was analyzed by Western blot analysis in A549, SW900,
H520 and DMS53 cell lines. (E,F) A549 and SW900 cells were treated with T21 at IC50 during different
time periods (4, 8, 16, 24 h) followed by survivin and XIAP expression analysis through Western blot
analysis. Results were obtained from at least three independent experiments. Bars represent the
mean ± SD. Statistically significant results are indicated as *, p-value < 0.05; **, p-value < 0.01 and
***, p-value < 0.001. (G) Subcutaneous tumors from implanted DMS53 cells in Crl:NU-Foxn1nu mice
were treated with 6 mg/kg of T21 every other day for 20 days. Tumor samples were stained against
survivin by immunohistochemistry. Representative illustrations are shown at 2×, 10×, 20× and 40×
magnifications, the scale bars correspond to 500, 500, 100 and 100 µm, respectively.
To further investigate whether the effect of T21 over survivin and XIAP expression was
simultaneous or not, SW900 and A549 were treated at their IC50 values for different time periods (4, 8, 16
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and 24 h). The results showed a progressive and sharp decrease of survivin in a time-dependent manner
in A549 and SW900, reaching a significant decrease at 24 h. Conversely, XIAP moderately decreased its
protein levels at 4 h and were stabilized over time in both cell lines (Figure 2E,F). Hence, these results
suggest that T21 potently inhibits survivin protein levels in a dose and time-dependent manner, whilst a
moderate XIAP inhibition is observed.
On the other hand, we proposed to analyze the decrease of survivin levels after T21 treatment in
subcutaneous tumors implanted in the flank of mice that were treated intraperitoneally with 6 mg/kg
of T21 every other day for 20 days. As observed in Figure 2G, T21 was able to considerably reduce
the protein levels of survivin in tumor samples from treated mice, which showed a decrease in tumor
growth. This result corroborates the molecular changes induced by T21 in vitro showing that T21
decreases the expression of survivin also in tumors. Additionally, these results confirm that T21 has
reached the tumors and suggest that survivin may be a good biomarker for T21 treatment efficacy.
3.3. T21 Reduces Survivin Levels via Gene Transcription Repression in Lung Cancer Cells
In order to identify the cellular mechanism that T21 was triggering to decrease survivin levels,
A549 and SW900 cell lines were treated with T21 IC50 for 6 and 16 h and BIRC5 gene expression was
analyzed by RT-qPCR. T21 was able to downregulate BIRC5 at both incubation periods albeit being
more evident at 16 h, indicating that T21 represses survivin gene expression (Figure 3A).Biomolecules 2019, 9, x FOR PEER REVIEW 10 of 17 
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increasing survivin expression levels and promoting tumorigenesis after aberrant activation in cancer 
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Figure 3. T21 reduces survivin levels through transcriptional repression. (A) A549 and SW900 cells
were treated with T21 at IC50 for 6 and 16 h and BIRC5 gene expression was analyzed by RT-qPCR.
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To further study whether the reduction of survivin levels observed after T21 exposure was only
due to a transcriptional repression, SW900 and A549 were treated with CHX, an inhibitor of protein
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synthesis. After 30 min of CHX treatment, cells were treated with T21 at IC50 for 24 h. As observed in
Figure 3B,C, survivin levels in both cell lines treated with T21 plus CHX were similar to CHX treated
cells. Hence, T21 was inducing the same effect that only inhibiting the de novo protein synthesis,
since no additional degradation was observed compared to CHX treated cells. Therefore, these results
suggest that the reduction of survivin levels after T21 exposure is mainly due to a transcriptional
repression and T21 is not triggering direct protein degradation.
3.4. T21 Suppresses STAT3 Phosphorylation via JAK/STAT3 Pathway Inhibition in Lung Cancer Cells
Among other signaling pathways, the JAK/STAT3 has been described to be involved in increasing
survivin expression levels and promoting tumorigenesis after aberrant activation in cancer cells [11].
In this regard, we first evaluated STAT3 activity in A549 and SW900 lung cancer cells, compared to
normal cells (HFL-1) (Figure 4A), observing a significant increase in basal STAT3 signaling in cancer
cells, accompanied by higher levels of survivin expression.
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Figure 4. STAT3 pathway analysis. (A) STAT3 signaling in lung normal and cancer cells. Levels
of phospho-STAT3 and survivin were analyzed by western blot in HFL-1, A549 and SW900 cells.
(B,C) JAK/STAT3 pathway inactivation after T21 treatment. fter 24 h of treatment with the IC25,
IC50, IC75 values of T21 ( able S1), the expression a osphorylation level of several members of
JAK1/STAT3 pathway were analyzed by Western blot in 549 and SW900 cells. Results were obtained
from at least three independent experiments. Bars represent the mean ± SD. Statistically significant
results are indicated as *, p-value < 0.05; **, p-value < 0.01 and ***, p-value < 0.001.
Then, in order to assess whether this pathway could be involved in survivin regulation after
T21 treatment, STAT3 phosphorylation at Tyr705 (p-STAT Y705) was evaluated in SW900 and A549
cells after T21 exposure at their IC25, IC50 and IC75 for 24 h. This phosphorylation allows STAT3
dimerization, nucleus translocation from cytoplasm, and DNA binding [12]. Both cell lines showed a
significant reduction in net phosphorylation of STAT3 at Tyr705 after T21 treatment in a dose-dependent
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manner (Figure 4B,C), similarly to that observed in survivin levels. Since STAT3 can be phosphorylated
by JAK, upon IL-6 stimulation and gp-130 receptor activation, phosphorylation status of this upstream
STAT3 activator was also evaluated. JAK1 showed a significant reduction on its phosphorylation state
at Tyr1034/1035 (p-JAK1 Y1034/1035). Similarly, JAK2 phosphorilation decreased after T21 treatment
(Figure S3). These results suggest that T21 inhibits STAT3 phosphorylation through JAK/STAT3 pathway,
which may reduce the gene expression of survivin provoking the observed protein level decrease.
3.5. T21 Blocks IL-6-Induced STAT3 Phosphorylation in A549
To examine whether T21 was also able to block STAT3 signaling after stimulating with one of its
upstream ligands, we first analyzed the IL-6 effects on STAT3 phosphorylation in lung cancer cells.
A549 cells, after starvation for at least 12 h to decrease the JAK/STAT signaling pathway, were stimulated
with IL-6 at different concentrations for 30 min. STAT3 was activated by phosphorylation in a
dose-dependent manner after IL-6 stimulation from 1 to 10 ng/mL (Figure 5A). In turn, the total STAT3
expression level was not altered with IL-6 stimulation. Next, in the same culture conditions after
starvation, A549 cells were pretreated with T21 at IC50 for 4 h followed by 5 ng/mL of IL-6 stimulation
for 30 min. The results showed that IL-6 treatment induced STAT3 phosphorylation, but this induction
was almost totally repressed by T21 in pretreated cells, showing that T21 pretreatment impedes
activation of this signaling pathway by IL-6 (Figure 5B,C).
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Figure 5. T21 blocks STAT3 activity fter IL-6 stim ation. (A) A549 cells were starved, then treated
with different concentrations of IL-6 and phosphorylation levels of STAT3 were assessed by Western
blot analysis. (B,C) after starvati , A549 were pretreat d with IC50 T21 for 4 h followed by 5 ng/mL
of IL-6 stimulation for 30 min. Phosphorylation levels of STAT3 were then assessed by Western blot
analysis. Bars represent the mean ± SD. Statistically sign ficant results are indicated as *, p-value < 0.05;
**, p-value < 0.01 and ***, p-value < 0.001. (D) A549 cells were pretreated with IC50 T21 for 4 h,
after starvation, followed by 5 ng/mL of IL-6 stimulation for 30 min. Subcellular localization of
phospho-STAT3 (Y705) was assessed by immunofluorescence staining. The framed regions are zoomed
in the bottom images. The line profiles of phospho-STAT3 (Y705) and Hoechst signals were measured
by ZEN 2.3 blue edition (Carl Zeiss) software. (Scale bars correspond to 10 µm).
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Additionally, to investigate whether T21 can block the IL-6-induced translocation of STAT3 from
cytoplasm to nucleus, A549 cells were pretreated with T21 at IC50 for 4 h followed by 5 ng/mL of IL-6
stimulation for 30 min. After cell fixation and immunofluorescence staining, phosphorylated STAT3 at
Tyr705 was increased and translocated into nucleus due to IL-6 stimulation (Figure 5D). By contrary,
cells stimulated with IL-6 after T21 treatment showed lower levels of phosphorylated STAT3 as well
as no significant translocation into the nucleus. Altogether, the above results suggest that T21 is able
to prevent IL-6-induced STAT3 phosphorylation and its nuclear translocation; hence T21 blocks the
JAK/STAT3 signaling pathway in lung cancer cells.
4. Discussion
Although there have been significant advances in lung cancer management in recent years,
lung cancer overall survival remains very low [13]. Hence, more efforts are needed to identify, design and
develop new compounds aimed at treating lung cancer. The development of new technologies are
aiding to find promising lead candidates from natural products, which have demonstrated to be a
major source for drug discovery along history [14]. Natural products and their bioactive derivatives
from animals, plants, fungi, and microorganisms, among others, have widely been studied for
therapeutic use, being the morphine the first commercial plant-derived product in 1826. Interestingly,
about a quarter of all Food and Drug Administration (FDA) and/or the European Medical Agency
(EMA) approved drugs are directly or indirectly plant based [15]. Natural-based products have
also been an important source of several clinically useful anti-cancer agents, as the well-known
antineoplastic paclitaxel that derives from endophytic fungi isolated from plants and is used for the
treatment of breast, ovarian and lung cancer. In this regard, we have recently described a marine
organism-derived small molecule called indole-based tambjamine analog 21 (T21), which possesses
a potent antitumor effect through the induction of apoptosis [6]. In accordance with our findings,
several studies also demonstrated the potential of compounds derived from marine organism as
anti-cancer agents, being some of these compounds in clinical trials and others already approved for
clinical use [4]. Various examples of approved antineoplastic analogs derived from marine organisms
include cytarabine (Cytosar), an antimetabolite drug used for the treatment of various types of leukemia;
trabectedin (Yondelis), a DNA alkylator for soft sarcoma treatment; and the antimitotic compounds
that inhibits microtubule dynamics eribulin mesylate (Halaven) and brentuximab vedotin (Acentris),
which are used in breast cancer and Hodgkin’s lymphoma treatment, respectively. Regarding the cell
death induced by T21, this pro-apoptotic compound significantly decreases survivin levels, also in
in vivo studies, inducing simultaneously a significant decrease in tumor volume without any obvious
toxicity in mice [6]. As a member of the inhibitor of apoptosis protein (IAP) family, survivin (protein
encoded by BIRC5) plays an important role in tumorigenesis, metastasis and therapy resistance [16,17].
Survivin is highly expressed during embryonic and fetal development, but is almost undetectable
in most normal finally differentiated tissues [8]. In cancer cells, survivin is overexpressed, being
associated with poor prognosis in many human neoplasms. Moreover, survivin also participates in
complex molecular signaling cascades cancer-related, being therefore crucial for carcinogenesis [18].
Altogether, the fact that survivin is overexpressed in tumors as well as its key biological roles that
promote carcinogenesis and chemoresistance, makes survivin a promising therapeutic target to treat
cancer [8]. In these sense, putative survivin antagonists under study are showing promising antitumoral
potential, such as YM155, a small-molecule inhibitor that targets and suppresses specifically the activity
of the survivin promoter [19]. Nevertheless, despite showing good clinical results in combination
regimens, YM155 and other survivin inhibitors under study present modest activity as a single agent,
which may be attributed to incomplete or transient survivin inhibition.
In order to characterize in depth the molecular mechanism by which this compound inhibits
survivin, we analyzed its effects on several lung cancer cells. Here, we show that T21 significantly
reduced the levels of survivin in all survivin overexpressing cells. Interestingly, T21 also induced a
decrease of survivin levels in vivo, suggesting an acceptable metabolism rate limiting biotransformation
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of this drug before exerting its effects. On the other hand, T21 was also able to reduce the levels of
XIAP, another IAP protein which interacts and forms a complex with survivin to inhibit the effector
caspases [20]. In this context, it has also been reported that this IAP-IAP complex enhances XIAP
stability against ubiquitin-dependent degradation [10]. Hence, T21 effect over survivin expression
and protein levels might be affecting the stability of XIAP, thus avoiding caspase inhibition and finally
promoting apoptosis. Furthermore, we showed how the effect of T21 on survivin was not due to
direct protein degradation but survivin gene repression. These results clearly categorize T21 as an
indirect inhibitor of survivin, like herceptin, lapatinib or SD-1029, among others, which downregulates
survivin expression targeting key cellular signaling pathways involved in the expression of this
protein [19,21–23].
In this regard, survivin gene regulation can be triggered by several signaling pathways, such as
PI3K/AKT, MAPK/ERK and JAK/STAT pathways [7]. Among them, STAT3 has been described as an
important signaling mediator in malignant diseases by promoting the expression of genes involved
in cancer proliferation, cell survival, immune suppression, inflammation, and metastasis [24,25].
Persistent activation of STAT3, which is found in 22–65% of NSCLC [26], induces survivin expression
and thereby prevents apoptosis, which potentially contributes to resistance to chemotherapy [11].
In this study, we found that T21 treatment could inhibit the STAT3 Tyr705 phosphorylation in NSCLC
cells. Interestingly, it has been proved that the acidification of the cytosol in A549 cells triggers a
rapid dephosphorylation of STAT3 at Tyr705 [27]. In this regard, T21 significantly decreases the
intracellular pH in A549 cells after 1 h, promoting the acidification of the cytosol [28]. Hence, the rapid
dephosphorylation of STAT3 at Tyr705 observed in our A549 cells may be a consequence of this
cytosolic acidification produced by T21. Moreover, since the transcriptional activity of STAT3 is closely
associated with this phosphorylation, the inhibition of the JAK/STAT3 pathway may be the cause of
the observed downregulation of survivin in our model. In fact, the repression of STAT3 transcriptional
activity after T21 treatment is also supported by our previous results, where other STAT3 downstream
genes, such as Bcl-2, Bcl-xL or Mcl-1 were also modified after treatment [6]. Furthermore, our results
are consistent with previous studies that already described a reduction of survivin in glioblastoma,
leukemia, NSCLC, breast and ovary cancers when JAK/STAT3 pathway was inhibited [23,29–32].
On the other hand, STAT3 activation is commonly triggered by the binding of growth factors
and cytokines to their specific receptors. IL-6, a pleiotropic cytokine, has been associated with STAT3
activation after its binding to the gp130 receptor, which in turn, recruits and triggers the activation
of JAK [33]. JAK can then phosphorylate STAT3 on Try705 residue, promoting its homodimerization
and translocation to the nucleus, followed by gene expression regulation [34]. Data from previous
studies have confirmed that elevated IL-6 levels are observed in patients with a variety of cancers [35].
In particular, IL-6 levels have been found increased in nearly 40% of lung cancer patients [36].
Furthermore, high levels of circulating IL-6 were associated with poor responses and worst survival
outcomes in NSCLC patients treated with chemotherapy [37]. In this study, we confirmed that IL-6
was able to phosphorylate STAT3 at Tyr705 as well as promote its nuclear translocation. Conversely,
both activation and nuclear translocation of STAT3 were repressed after T21 treatment, suggesting that
T21 may help to overcome the chemoresistance of tumors with high IL-6 levels.
5. Conclusions
We have investigated in detail the molecular mechanisms of action by which the novel anticancer
drug T21 inhibits the antiapoptotic protein survivin in vitro as well as in vivo and have validated this
protein as a promising therapeutic target for lung cancer treatment. As a result, we have demonstrated
that JAK/STAT3 signaling pathway is the molecular mechanism involved in the inhibition of survivin
by T21. T21 regulates survivin by transcriptional gene repression, blocking the phosphorylation of
STAT3 and its nuclear translocation. Moreover we have shown that STAT3 inhibition by T21 is effective
even in the presence of IL-6 overstimulation. These findings reinforce the potential of T21 as a novel
chemotherapeutic agent for lung cancer treatment, especially for lung cancer patients with high levels
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of IL-6, who show poor outcomes in the clinics. Altogether, T21 is a novel potent inhibitor of STAT3
transcription factor that significantly decreases survivin levels, which may sensitize cancer cells to
apoptosis and may enhance the apoptotic effect induced by traditional chemotherapeutic drugs in
lung cancer patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/9/8/361/
s1, Figure S1: Survivin overexpression validation by immunofluorescence in HFL-1, A549 and SW900 cells.
Figure S2: Effects of T21 on cell viability by a clonogenic assay. Figure S3: JAK2 activity after T21 treatment.
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